Stacy Hurt: Parexel is under consideration for the 2024 SCRS Eagle Award

Stacy Hurt shared on X/Twitter:

“Parexel is proud to be under consideration for the 2024 SCRS Eagle Award, recognizing CROs and sponsors for outstanding leadership, professionalism, integrity, passion and dedication to advancing clinical research through strong site partnerships. We’re committed to working together with site partners across the clinical development process to create a better experience for patients and bring forward innovative new medicines.

Site partners, please consider casting your vote for Parexel in the SCRS survey, available until July 31. Thank you for your support and consideration ─ we couldn’t do what we do without you!”

Source: Stacy Hurt/X

Stacy Hurt is a Global Annual Meeting Program Committee member for Drug Information Association (DIA) and co-chair of the board for the American Cancer Society Northeast Region (Pittsburgh market). Stacy’s impact earned her a spot on Fierce Pharma’s 2023 Fierce 50 list as a Patient Advocacy Honoree.